Therefore, for SAMEN ROM calculation purposes, we made an FNAB-based assumption that there were six malignancies in the non-surgical group of 90 (2 Bethesda VI cytologic results, one BRAF V600E mutation, and five Bethesda III/IV cytologic results with a 50% risk of malignancy based on uspicious AFIRMA GEC or GSC for a total of 5.5 malignancies, which we rounded up to six prior to ROM calculation). This evidence concerns the gene BRAF and cancer.